Fig. 3: In the presence of bevacizumab and TLR4 agonists, macrophages polarize to the M2b subtype in vitro. | Cell Death & Disease

Fig. 3: In the presence of bevacizumab and TLR4 agonists, macrophages polarize to the M2b subtype in vitro.

From: Tumor necrosis factor α inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer

Fig. 3

a Representative analysis of the bevacizumab binding mouse macrophages (bevacizumab-FITC, CD11b-PE). b Flow cytometry analysis of CD86, CD11b and IL10 expression in macrophages treated with bevacizumab and PBS respectively. (CD11b-PE, CD86-FITC, IL10-APC). c Representative image and quantitative evaluation of tumor sections from mice treated with bevacizumab and PBS stained for HMGB1 at 8-week. Scale bar, 100 μm. *P < 0.05 by t test. Error bars represent s.d. d Analysis of the RAW264.7 macrophages treated with bevacizumab, F(ab′)2 of bevacizumab, human IgG, alone or in combination with LPS for 48 h. Cells were stained for CD11b, CD86, and intracellular IL10.

Back to article page